The facts
The FDA issued a warning letter on October 13, 2026 to Lovelace Biomedical Research Institute (LBRI) in Albuquerque, addressed to CEO Robert W. Rubin. The letter documents an April 7‑18, 2025 inspection under the Bioresearch Monitoring Program and cites violations of 21 CFR 58.35(b)(6) because the quality assurance unit (QAU) did not verify that final study reports matched raw data. For one protocol, the final report omitted abnormal cageside observations for 20 of 34 animals recorded between October 1, 2023 and January 3, 2024, including runny or bloody noses, sunken eyes, hunched posture and heavy breathing, as well as dosing incidents such as Animal 3002 lying on the cage floor for over an hour after infusion and Animals 3004‑3005 pulling out venous catheters. For a second protocol, the final report failed to include abnormal stool observations - such as bloody, dark‑red, liquid or mucoid stools - recorded for several animals between November 21, 2022 and July 13, 2023, and omitted inhalation‑dosing issues like irregular breathing and a swollen muzzle that prevented dosing. LBRI’s May 9, 2025 response promised addenda and SOP updates, but the FDA deemed the corrective plan inadequate, noting missing details on SOP revisions, training, and audit plans.
Our take
The FDA’s definition of the Quality Assurance Unit’s job is as blunt as a fucking sledgehammer: make sure the final report actually mirrors the raw data. At Lovelace Biomedical, the QAU looked at a study where 20 out of 34 critters were sneezing, bleeding from their noses, hunched over, and struggling to breathe, and they signed off like nothing. They also ignored that Animal 3002 spent an hour flat on the cage floor after a dose, and that a couple of animals yanked their own IV lines out mid‑infusion. Then there’s the second protocol where abnormal stool - bloody, dark‑red, mucoid - was recorded for a swath of animals, yet the final report pretended the animals had perfectly normal bowels. The agency’s response was a classic your fix is a lazy, transparent lie moment, calling the corrective plan inadequate because it lacked specifics on SOP updates, training, and future audits. In other words, the lab’s paperwork is cleaner than a porn star’s colon after a prep, while the raw data reads like a horror flick. This isn’t a simple oversight; it’s a systemic decision to hide suffering and compromise data integrity. When the very purpose of non‑clinical safety studies is to flag toxic effects before human trials, omitting nose bleeds, stool anomalies and dosing mishaps turns the process into a crime scene with a cover‑up authored by absolute cunts. The FDA’s warning is a rare glimpse of accountability, but without concrete corrective actions, the risk remains that future studies will continue to be sanitized, endangering downstream drug development and, ultimately, patients.
